Evolent Health FY 2025 earnings snapshot

Evolent Health (EVH) closed FY 2025 with fourth quarter revenue of US$468.7 million and a basic EPS loss of US$3.84, as the company continued to report negative net income. Over recent periods, revenue has ranged from US$444.3 million to US$483.6 million per quarter, while quarterly basic EPS has stayed in loss-making territory between US$0.24 and US$3.84. This gives investors a clear view of the trade off between top line scale and ongoing earnings pressure. With revenue holding near the US$450 million to US$480 million range but margins still under strain, attention now turns to how management describes the path to improving profitability from here.

See our full analysis for Evolent Health.

With the latest numbers on the table, the next step is to assess how this earnings profile compares with the dominant bull and bear stories around Evolent Health and where those narratives might need updating.

Trailing 12‑month loss reaches US$579 million

• On a trailing 12 month basis, Evolent Health reported total revenue of about US$1.9b and a net loss of US$579.4 million, with basic EPS at a loss of US$5.07 for FY 2025.
• Consensus narrative talks about revenue growing around 10.8% a year and profit margins potentially moving from an 8.4% loss to an 8.8% profit. However, the current US$579.4 million loss and US$5.07 EPS loss show that any margin improvement story is starting from a deeply loss making position, which investors will want to line up carefully against those margin targets.

15% revenue growth vs five year loss trend

• Revenue is cited as growing around 15% a year over the last year, while five year net losses have grown at roughly 21.2% a year, so top line expansion has come alongside a faster worsening in losses over that multi year period.
• For the bullish view that earnings could grow at about 110% a year and potentially turn profitable within three years, the tension is that the company has US$579.4 million of trailing losses and a recent quarterly loss of US$429.1 million. Bulls therefore need to be comfortable that the same revenue growth that coincided with worsening losses can, over time, support the margin improvement they are expecting.

Have bulls called the turn correctly, or are the current US$579 million in losses a sign that the margin story will take longer to play out? 🐂 Evolent Health Bull Case

Low P/S against DCF fair value gap

• Shares trade on a P/S of 0.2x versus peer and industry averages of 2.2x, and the stated DCF fair value of US$10.51 sits well above the current US$3.14 share price, pointing to a very wide valuation gap based on those inputs.
• Bears highlight ongoing unprofitability and widening losses over five years as reasons this low multiple could persist, and the current US$579.4 million trailing loss together with the sharp US$3.84 EPS loss in Q4 show why that caution exists. This is the case even though the 0.2x P/S and gap to the US$10.51 DCF fair value might catch the eye of investors who focus heavily on valuation metrics.

Are bears right that the US$579 million loss justifies a 0.2x P/S, or is the current price missing something that the DCF fair value is picking up? 🐻 Evolent Health Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Evolent Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of losses, growth and valuation has you torn, take a moment to look through the underlying data yourself and pressure test the assumptions. Acting sooner rather than later can help you form a clearer stance, especially when our work highlights 3 key rewards.

See What Else Is Out There

Evolent Health is still working through sizeable losses, with a trailing 12 month net loss of US$579.4 million and a recent quarterly loss of US$429.1 million.

If that level of ongoing red ink makes you want more resilient ideas, use our 80 resilient stocks with low risk scores to quickly spot companies with steadier profiles and fewer financial shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.